How Much Weight Can You Lose on Semaglutide?

Semaglutide Weight Loss

14.9% body weight

In the STEP 1 trial, 1,961 adults without diabetes lost an average of 14.9% of their body weight on semaglutide 2.4 mg over 68 weeks, compared to 2.4% on placebo.

Wilding et al., New England Journal of Medicine, 2021

Wilding et al., New England Journal of Medicine, 2021

View as image

Semaglutide 2.4 mg (marketed as Wegovy) is the most studied GLP-1 receptor agonist for weight management, with over 4,500 participants enrolled across the STEP clinical trial program. The weight loss results are consistent across trials: approximately 15% of body weight at the 2.4 mg weekly dose in people without diabetes.^[1] But averages obscure important variability. Some participants lost 20%+ of their body weight. Others lost less than 5%. This article presents the trial-by-trial data so you can see exactly what was measured, in which populations, and over what timeframes. For how semaglutide works at the receptor level, see our pillar article on semaglutide for weight loss without diabetes.

STEP 1: the landmark trial

The STEP 1 trial (Semaglutide Treatment Effect in People with Obesity) is the largest and most cited semaglutide weight loss study. Wilding et al. published the results in the New England Journal of Medicine in 2021.^[1]

Participants: 1,961 adults with BMI of 30 or greater (or 27+ with at least one weight-related condition) without diabetes. Mean baseline weight was approximately 105 kg (231 lbs). Mean BMI was 37.9.

Treatment: Once-weekly subcutaneous semaglutide 2.4 mg or placebo for 68 weeks, with all participants receiving lifestyle intervention (reduced-calorie diet and increased physical activity counseling).

Results:

• Mean weight loss: 14.9% with semaglutide vs 2.4% with placebo
• Absolute weight loss: 15.3 kg (33.7 lbs) vs 2.6 kg (5.7 lbs)
• Weight loss of 5% or more: 86.4% vs 31.5%
• Weight loss of 10% or more: 69.1% vs 12.0%
• Weight loss of 15% or more: 50.5% vs 4.9%
• Weight loss of 20% or more: 32.0% vs 1.7%

The 5% weight loss threshold is clinically meaningful because it is associated with improvements in blood pressure, blood sugar, cholesterol, and sleep apnea severity. Achieving 15%+ is associated with potential remission of type 2 diabetes and resolution of obstructive sleep apnea.

STEP 5: the 2-year durability data

STEP 1 lasted 68 weeks (about 16 months). STEP 5 answered the critical follow-up question: does weight loss persist with continued treatment?^[2]

Participants: 304 adults, same eligibility as STEP 1. Randomized 2:1 to semaglutide 2.4 mg or placebo for 104 weeks (2 years).

Results at 104 weeks:

• Mean weight loss: 15.2% with semaglutide vs 2.6% with placebo
• The weight loss trajectory showed maximum effect at approximately 60-68 weeks, with weight remaining stable (not rebounding) through week 104 with continued treatment

This is the longest controlled semaglutide weight loss data available. It confirms that the effect does not wear off with continued use and that there is no significant weight rebound while on treatment. The 15.2% at 2 years is nearly identical to the 14.9% at 68 weeks in STEP 1, suggesting a plateau rather than progressive loss.

For what happens after stopping treatment, see our article on semaglutide weight regain after discontinuation.

How semaglutide compares to tirzepatide

The SURPASS-2 trial directly compared tirzepatide (now marketed as Mounjaro/Zepbound) against semaglutide 1 mg in patients with type 2 diabetes.^[3] This was not a head-to-head at the approved weight loss doses (semaglutide 2.4 mg vs tirzepatide 15 mg), but it provides the closest comparison available.

At 40 weeks:

• Tirzepatide 5 mg: -7.6 kg
• Tirzepatide 10 mg: -9.3 kg
• Tirzepatide 15 mg: -11.2 kg
• Semaglutide 1 mg: -5.7 kg

All tirzepatide doses produced greater weight loss than semaglutide 1 mg. The SURMOUNT-1 trial of tirzepatide 15 mg in people without diabetes showed 22.5% mean weight loss at 72 weeks, exceeding semaglutide's 14.9% in STEP 1.

The comparison is imperfect because the semaglutide dose in SURPASS-2 (1 mg, the diabetes dose) is lower than the weight management dose (2.4 mg). A true head-to-head of semaglutide 2.4 mg vs tirzepatide 15 mg has not been published.

The variability problem: not everyone responds equally

Trial averages mask wide variability in individual responses. In STEP 1:

• 86.4% lost at least 5% body weight (responders by clinical threshold)
• 13.6% lost less than 5% (relative non-responders)
• At the high end, 32% lost 20% or more of body weight
• A small percentage gained weight despite treatment

Factors associated with greater weight loss in post-hoc analyses include higher baseline BMI, female sex, better adherence to lifestyle modification, and absence of type 2 diabetes. People with type 2 diabetes consistently lose less weight on GLP-1 agonists than those without diabetes, likely because insulin resistance and diabetes medications (particularly insulin and sulfonylureas) promote weight retention.

Singh et al.'s 2022 review summarized the STEP program outcomes and noted that semaglutide's efficacy was consistent across subgroups defined by age, sex, race, baseline BMI, and the presence of weight-related conditions.^[4]

Weight loss trajectory: when to expect results

Across the STEP trials, weight loss follows a predictable trajectory:

• Weeks 1-4: Dose escalation phase. Starting at 0.25 mg weekly, increasing every 4 weeks. Minimal weight loss. Some appetite reduction begins.
• Weeks 4-16: Accelerating weight loss as dose increases toward the maintenance dose of 2.4 mg. Most participants begin noticing reduced appetite and earlier satiety.
• Weeks 16-40: Most rapid weight loss phase. Body weight drops approximately 1% per month at this stage.
• Weeks 40-68: Weight loss decelerating, approaching plateau. Monthly losses slow to 0.3-0.5%.
• Weeks 68+: Weight stabilization. STEP 5 confirmed that weight remains stable through 104 weeks with continued treatment.

For a detailed guide to the dose escalation schedule, see our article on semaglutide dose escalation. For what the body composition changes look like, see our article on fat loss versus muscle loss on semaglutide.

What 14.9% weight loss looks like in real numbers

To make the percentage concrete:

The average STEP 1 participant started at 231 lbs and lost 33.7 lbs over 68 weeks. For participants in the top third of responders (20%+ loss), a 231-lb person would have lost 46+ lbs.

Real-world versus trial results

Clinical trial results typically exceed real-world outcomes because trials select motivated participants, provide regular follow-up, and enforce adherence. Early real-world studies of semaglutide for weight management show 10-12% weight loss at 12 months, compared to 14.9% in the controlled STEP 1 setting.

The gap is expected and consistent with other pharmacotherapy data. Real-world patients may start and stop treatment, miss doses, use lower doses due to side effects, and receive less intensive lifestyle counseling. The 10-12% real-world figure still represents clinically meaningful weight loss that exceeds any previously available pharmacotherapy.

For what the full range of GLP-1 side effects looks like across clinical trials, see our dedicated article.

The Bottom Line

Semaglutide 2.4 mg produces approximately 15% body weight loss at 68 weeks in people without diabetes, based on the STEP clinical trial program enrolling over 4,500 participants. Half of treated participants lose 15% or more. The effect persists at 2 years with continued treatment (STEP 5). Response varies widely: 86% achieve clinically meaningful 5%+ loss, but 14% do not reach this threshold. Tirzepatide produces greater weight loss (22.5% in SURMOUNT-1) but has not been directly compared at equivalent weight management doses. Real-world results (10-12%) are modestly lower than trial results, consistent with reduced adherence and follow-up intensity outside controlled settings.

Frequently Asked Questions

How much weight do you lose on semaglutide?

In the STEP 1 clinical trial, adults without diabetes lost an average of 14.9% of their body weight (15.3 kg or 33.7 lbs) on semaglutide 2.4 mg over 68 weeks. Half of participants lost 15% or more. Real-world studies show somewhat lower results of 10-12% at 12 months, reflecting differences in adherence and follow-up intensity.

How long does it take to see weight loss on semaglutide?

Most participants begin noticing weight loss during the dose escalation phase (weeks 4-16), with the most rapid loss occurring between weeks 16 and 40 as the full 2.4 mg dose takes effect. Weight loss approaches a plateau around weeks 60-68. The full treatment effect is typically apparent by month 12-16.

Does semaglutide work for everyone?

In the STEP 1 trial, 86.4% of participants achieved at least 5% weight loss, the clinically meaningful threshold. This means 13.6% did not reach this benchmark. Response varies by individual factors including baseline BMI, sex, diabetes status, and adherence to lifestyle modification. People with type 2 diabetes consistently lose less weight on semaglutide.

Is semaglutide or tirzepatide better for weight loss?

The available data suggests tirzepatide produces greater weight loss. SURMOUNT-1 showed 22.5% weight loss with tirzepatide 15 mg versus 14.9% with semaglutide 2.4 mg in STEP 1. However, these are separate trials with different populations, not a direct head-to-head comparison at approved weight management doses. In the SURPASS-2 head-to-head for diabetes, all tirzepatide doses beat semaglutide 1 mg.

Do you keep the weight off on semaglutide?

The STEP 5 trial showed that weight loss was maintained at 15.2% through 104 weeks (2 years) with continued semaglutide treatment. Weight does not rebound while on the drug. However, discontinuation studies show that most weight returns within 1-2 years after stopping treatment, suggesting semaglutide requires ongoing use for sustained effect.

What is the maximum weight loss on semaglutide?

In STEP 1, 32% of participants lost 20% or more of their body weight on semaglutide 2.4 mg. Individual results ranged widely, with some participants losing over 25% of body weight. The average starting weight was 231 lbs, meaning top responders lost over 46 lbs. Maximum recorded losses in the trials were not individually reported.